About Us
Scroll to: Vision/Mission | Research | People | Partners | Nodes
Vision
Development of new radiochemical technology relies on fundamental chemistry to design, synthesise and manufacture molecules which interface with the fields of biology, toxicology and formulation science. Novel chemistry exploiting molecular incorporation of radioactive elements, stable chelation of metal radionuclides, bioconjugation methodologies, radioactivity capture via nanomaterials and cages, and the design of new peptidomimetic targeting molecules will deliver technological advances to radiopharmaceutical science.
Mission
The ARC Training Centre for Development of Advanced Radiochemical Technologies (DART) aims to:
- Train the next generation of highly skilled scientists that will drive continued innovation in radiochemistry and provide the transformative technologies that are essential to Australia’s manufacture of high-value biologically active radiochemical agents and radiopharmaceuticals;
- Train new scientific leaders through a dynamic and symbiotic combination of mentorship and training from leading academics and 7 government/industry partners;
- Discover new molecular approaches to harness radioactivity; and
- Enhance commercial capacity to meet domestic need and a rapidly escalating global radiopharmaceutical market.
Research Focus
Partners
Research Centres
ANSTO leverages great science to deliver big outcomes. We partner with scientists and engineers and apply new technologies to provide real-world benefits. Our work improves human health, saves lives, builds our industries and protects the environment. ANSTO is a leading player in the development and translation of radiopharmaceuticals to improve the detection and diagnosis of disease. ANSTO has the expertise and capabilities to supply radioisotopes and undertake radiochemistry, radiation biology and preclinical imaging studies to develop and evaluate radiopharmaceuticals. This includes the use of new radioisotopes from the OPAL multipurpose reactor.
The Helmholtz-Zentrum Dresden-Rossendorf is a modern large-scale research centre located at the northeastern outskirts of Dresden, Germany. Almost 700 scientists from more than 70 nations conduct cutting-edge research with a
long-term focus in the fields of energy, health and matter, which is funded by the German Federal Government as well as the Free State of Saxony. As a member of the Helmholtz Association of German Research Centres, HZDR has the
mission to deliver solutions to the great challenges of our time including a substantial contribution to a healthy society with novel diagnostic and therapeutic methods in cancer research.
Industry Partners
GlyTherix Ltd is a targeted radiotherapy company with a clinical stage product showing an excellent safety profile in high unmet need cancers. Our antibody, Miltuximab® specifically targets GPC-1, a protein found on solid tumours such as prostate, bladder, pancreatic, glioblastoma, oesophageal and ovarian cancers, and is not present in healthy tissue.
iPHASE technologies is a world class designer and manufacturer of automated instrumentation for P.E.T. radiochemistry. By using the latest automation technologies coupled together with intelligent design and class leading software interfaces, our instrumentation is built by users for users.
Nodes
Our Centre spans across three universities in two states to allow our students a breadth of researchers to work with.
